Kok Hoe Chan

Dr. Kok Hoe Chan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
KCKok Hoe Chan
Kok Hoe Chan
IFIyad Farouji
Iyad Farouji
AHAmany Abu Hanoud
Amany Abu Hanoud
JSJihad Slim
Jihad Slim

1 December 2020 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
KCKok Hoe Chan
Kok Hoe Chan
SLSu Lin Lim
Su Lin Lim
ADAhmad Damati
Ahmad Damati
SMSiva Prasad Maruboyina
Siva Prasad Maruboyina
LBLeena Bondili
Leena Bondili
JSJihad Slim
Jihad Slim

1 August 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
KCKok Hoe Chan
Kok Hoe Chan
DTDivya Thimmareddygari
Divya Thimmareddygari
ARAmr Ramahi
Amr Ramahi
LALiana Atallah
Liana Atallah
NBNicholas G. Baranetsky
Nicholas G. Baranetsky
JSJihad Slim
Jihad Slim

24 May 2021 in Cureus
Verified
Journal Article
Open access
KCKok Hoe Chan
Kok Hoe Chan
BPBhavik Patel
Bhavik Patel
BPBishnu Podel
Bishnu Podel
MSMaria E Szablea
Maria E Szablea
HSHamid S. Shaaban
Hamid S. Shaaban
JSJihad Slim
Jihad Slim
Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, has been used in patients with coronavirus disease 2019 (COVID-19) as an anti-cytokine agent. IL-6 also plays a complex role in hemostasis and thrombosis. We observed a transient elevation of D-dimer in our patients who received tocilizumab, which triggered this study. A retrospective hospital-based cohort analysis of patients with confirmed COVID-19 who received tocilizumab during the study period of March 15, 2020, to May 20, 2020, was conducted. We retrieved demographic, clinical, and laboratory data, and patients who were receiving therapeutic anticoagulation therapy prior to tocilizumab administration were excluded. Descriptive analysis was performed, and the cause of death and trends of D-dimer and inflammatory markers were studied. Out of the 436 confirmed COVID-19 patients admitted during the study period, 24 met the inclusion criteria. Their median age was 47.5 years. They were 18 males and 6 females; 15 patients survived and nine expired. Of the group that survived, 12 received therapeutic anticoagulation. Of the seven patients who did not receive therapeutic anticoagulation, four expired (one from sepsis and three probably from thromboembolic complications) compared to five deaths in the 17 patients who received therapeutic anticoagulation (four from sepsis and one possibly from thromboembolic complications). The interplay between IL-6, IL-6 receptor antagonist, and venous thromboembolism is complex. We observed a transient elevation of D-dimer in COVID-19 patients who received tocilizumab, and a trend toward increased death secondary to thromboembolism. This observation is novel and highlights the potential thrombophilic side effects of tocilizumab.

1 September 2020 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
SLSaraswathi Lakkasani
Saraswathi Lakkasani
KCKok Hoe Chan
Kok Hoe Chan
HSHamid S. Shaaban
Hamid S. Shaaban
Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020

1 March 2021 in Cureus
Verified
Journal Article
Open access
PDF file
RARaed Atiyat
Raed Atiyat
SVSindhusha Veeraballi
Sindhusha Veeraballi
NANeveen Al-Atiyat
Neveen Al-Atiyat
KCKok Hoe Chan
Kok Hoe Chan
JSJihad Slim
Jihad Slim
Sudden, involuntary spasm of the diaphragm associated with closure of the glottis will lead to a hiccup sound. Brief episodes of hiccups are often self-limiting and may be physiologically encountered in everyday life. However, prolonged attacks of hiccups are associated with significant morbidity. Herein, we present a rare and interesting case of coronavirus disease 2019 (COVID-19) induced persistent hiccups in a 61-year-old gentleman with no signs or symptoms of gastric pathology. As the patient required less oxygen supplementation, with inflammatory markers down-trending, his hiccups improved. The timeline of the symptom presentation and his response to treatment highly suggested that his hiccups were associated with COVID-19 infection. To the best of our knowledge, there are only two cases of persistent hiccups secondary to COVID-19 that have been reported thus far. Our case will add to the existing literature and highlight the potential association of COVID-19 with hiccups.